Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Sebastian Schneeweiss, Sc.D., M.D.


This page shows the publications co-authored by Sebastian Schneeweiss and Alexander Walker.
Connection Strength

  1. Schneeweiss S, Carver PL, Datta K, Galar A, Johnson MD, Johnson MG, Marty FM, Nagel J, Najdzinowicz M, Saul M, Shoham S, Silveira FP, Varughese CA, Wilck M, Weatherby L, Auton T, Walker AM. Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. J Antimicrob Chemother. 2016 10; 71(10):2938-44.
    View in: PubMed
    Score: 0.733
  2. Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med. 2008 Feb 21; 358(8):771-83.
    View in: PubMed
    Score: 0.410
  3. Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ. 2002 Mar 19; 166(6):737-45.
    View in: PubMed
    Score: 0.272
  4. Walker AM, Schneeweiss S, DerSarkissian M, Duh MS. Removal of ineligible outcome cases reduces confounding. Clin Epidemiol. 2018; 10:575-579.
    View in: PubMed
    Score: 0.208
  5. Wang SV, Kulldorff M, Glynn RJ, Gagne JJ, Pottegård A, Rothman KJ, Schneeweiss S, Walker AM. Reuse of data sources to evaluate drug safety signals: When is it appropriate? Pharmacoepidemiol Drug Saf. 2018 06; 27(6):567-569.
    View in: PubMed
    Score: 0.207
  6. Martin D, Gagne JJ, Gruber S, Izem R, Nelson JC, Nguyen MD, Ouellet-Hellstrom R, Schneeweiss S, Toh S, Walker AM. Sequential surveillance for drug safety in a regulatory environment. Pharmacoepidemiol Drug Saf. 2018 07; 27(7):707-712.
    View in: PubMed
    Score: 0.205
  7. Bell C, Chakravarty A, Gruber S, Heckbert SR, Levenson M, Martin D, Nelson JC, Pinheiro S, Psaty BM, Reich CG, Schneeweiss S, Shoaibi A, Toh S, Walker AM. Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems. Pharmacoepidemiol Drug Saf. 2014 Nov; 23(11):1223-5.
    View in: PubMed
    Score: 0.162
  8. Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology. 2012 Mar; 23(2):238-46.
    View in: PubMed
    Score: 0.135
  9. Gagne JJ, Walker AM, Glynn RJ, Rassen JA, Schneeweiss S. An event-based approach for comparing the performance of methods for prospective medical product monitoring. Pharmacoepidemiol Drug Saf. 2012 Jun; 21(6):631-9.
    View in: PubMed
    Score: 0.134
  10. Schneeweiss S, Walker AM, Seeger JD. Effect of aprotinin on renal dysfunction. Lancet. 2008 Jul 05; 372(9632):26; author reply 26-7.
    View in: PubMed
    Score: 0.105
  11. Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther. 2003 Oct; 74(4):388-400.
    View in: PubMed
    Score: 0.076
  12. Schneeweiss S, Maclure M, Soumerai SB, Walker AM, Glynn RJ. Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance. J Clin Epidemiol. 2002 Aug; 55(8):833-41.
    View in: PubMed
    Score: 0.070
  13. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002 Mar 14; 346(11):822-9.
    View in: PubMed
    Score: 0.068
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.